ARVINAS, INC.
ARVNNasdaq
$8.01
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +5.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$512.6M
Enterprise Value
-$101.8M
P/E
—
P/S
5.7
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
-50.1%
Dividend Yield
—
Revenue (TTM)
$89.4M
Net Income (TTM)
-$221.5M
Free Cash Flow (TTM)
-$256.9M
Gross Margin
—
Operating Margin
-283.8%
Net Margin
-247.8%
ROE
-57.3%
ROIC
—
Debt / Equity
0.0
Net Cash
$614.4M
Return 1Y
+3.2%
Company profile
Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)
- CEO
- John G. Houston
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 420
- Headquarters
- Connecticut
- Website
- arvinas.com
Management & directors
- Saik AndrewChief Financial Officer
- Cacace Angela MChief Scientific Officer
- Teel RandyPresident and CEO
- Berkowitz NoahChief Medical Officer
- Loomis David KVP, Chief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
ARVN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15.6M↓ -91.7%
Diluted EPS-$0.90↓ -178.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $25.9M | $53.6M | $131.4M | $78.5M | $263.4M | $262.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$120.8M | -$188.4M | -$263.2M | -$401.5M | -$250.2M | -$118.5M |
| Net income | -$119.3M | -$191.0M | -$283.0M | -$367.0M | -$199.0M | -$81.0M |
| Diluted EPS | -$3.02 | -$3.82 | -$5.31 | -$6.62 | -$2.77 | -$1.14 |
| Operating cash flow | -$89.7M | $559.4M | -$273.5M | -$347.8M | -$259.3M | -$273.8M |
| Free cash flow | -$96.1M | $554.7M | -$280.3M | -$350.7M | -$261.1M | -$275.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -466.4% | -351.5% | -200.3% | -511.5% | -95.0% | -45.1% |
| Net margin | -460.6% | -356.3% | -215.4% | -467.5% | -75.6% | -30.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76.5M | $102.4M | $59.2M | $188.8M | $22.4M | $41.9M | $9.5M | $15.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$48.5M | -$60.3M | -$58.1M | $71.4M | -$71.5M | -$43.8M | -$74.6M | -$63.8M |
| Net income | -$35.2M | -$49.2M | -$45.2M | $82.9M | -$61.2M | -$35.1M | -$67.6M | -$57.6M |
| Diluted EPS | -$0.49 | -$0.68 | -$0.63 | $1.14 | -$0.84 | -$0.48 | -$0.96 | -$0.90 |
| Operating cash flow | $50.3M | -$128.0M | -$84.1M | -$88.9M | -$95.4M | -$59.1M | -$30.4M | -$69.2M |
| Free cash flow | $49.6M | -$128.7M | -$84.4M | -$89.3M | -$96.6M | -$59.2M | -$30.6M | -$70.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -63.4% | -58.9% | -98.1% | 37.8% | -319.2% | -104.5% | -785.3% | -409.0% |
| Net margin | -46.0% | -48.0% | -76.4% | 43.9% | -273.2% | -83.8% | -711.6% | -369.2% |
Company news
Jun 18, 2026
Jun 16, 2026
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-24 | Saik Andrew· Chief Financial Officer | Sale | 5,696 | $8.16 | $46,473.66 | filing |
| 2026-06-24 | Norwalk Leslie V | Award | 15,527 | $0.00 | $0.00 | filing |
| 2026-06-24 | Morrison Briggs | Award | 15,527 | $0.00 | $0.00 | filing |
| 2026-06-24 | Smaldone Alsup Laurie | Award | 15,527 | $0.00 | $0.00 | filing |
| 2026-06-24 | Cunningham Everett | Award | 15,527 | $0.00 | $0.00 | filing |
| 2026-06-24 | Bain Linda | Award | 15,527 | $0.00 | $0.00 | filing |
| 2026-06-24 | Kennedy Edward Moore Jr. | Award | 15,527 | $0.00 | $0.00 | filing |
| 2026-06-17 | Cacace Angela M· Chief Scientific Officer | Sale | 2,576 | $7.60 | $19,564.72 | filing |
| 2026-05-21 | Teel Randy· President and CEO | Sale | 2,209 | $9.04 | $19,961.63 | filing |
| 2026-05-11 | Saik Andrew· Chief Financial Officer | Sale | 11,139 | $9.94 | $110,692.70 | filing |
| 2026-05-11 | Berkowitz Noah· Chief Medical Officer | Sale | 11,108 | $9.94 | $110,384.64 | filing |
| 2026-05-11 | Cacace Angela M· Chief Scientific Officer | Sale | 9,657 | $9.94 | $95,965.47 | filing |
| 2026-05-11 | Teel Randy· President and CEO | Sale | 9,657 | $9.94 | $95,965.47 | filing |
| 2026-05-11 | Loomis David K· VP, Chief Accounting Officer | Sale | 1,919 | $9.94 | $19,069.87 | filing |
| 2026-03-18 | Berkowitz Noah· Chief Medical Officer | Sale | 6,435 | $11.10 | $71,431.07 | filing |
| 2026-03-06 | Morrison Briggs | Buy | 20,000 | $13.40 | $268,070.00 | filing |
| 2026-02-27 | Houston John G | Sale | 18,822 | $13.24 | $249,203.28 | filing |
| 2026-02-27 | Houston John G | Sale | 11,787 | $13.14 | $154,881.18 | filing |
| 2026-02-27 | Houston John G | Sale | 4,688 | $13.24 | $62,069.12 | filing |
| 2026-02-26 | Cacace Angela M· Chief Scientific Officer | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-26 | Berkowitz Noah· Chief Medical Officer | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-26 | Teel Randy· President and CEO | Award | 147,791 | $0.00 | $0.00 | filing |
| 2026-02-26 | Saik Andrew· Chief Financial Officer | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-26 | Teel Randy· President and CEO | Award | 147,179 | $0.00 | $0.00 | filing |
| 2026-02-26 | Loomis David K· VP, Chief Accounting Officer | Award | 12,420 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.